Finding Description
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** 4. Review of Resident #53's clinical record revealed the facility admitted the resident on [DATE] with diagnoses including Chronic Obstructive Pulmonary Disease with Acute Exacerbation, Dementia with Behavioral Disturbance, Major Depressive Disorder, and Restlessness and Agitation.
Review of Resident #53's CCP, revealed a focus of psychotropic drug use with an initiation date of [DATE]. The goal stated the resident would be/remain free of psychotropic drug related complications. The interventions included: administer psychotropic medications as ordered by physician; monitor for side effects and effectiveness; monitor/document/report as needed any adverse reactions of psychotropic medications; Psych to see as needed; consult with pharmacy and Physician to consider dosage reduction when clinically appropriate at least quarterly; and monitor/record occurrence of target behavior symptoms and document per facility protocol.
Review of Resident #53's CCP, revealed a focus related to Anxiety Disorder with an initiation date of [DATE]. The goal stated the resident would be free from discomfort or adverse reactions related to anti-anxiety therapy through the review date. The interventions included: administer anti-anxiety medications as ordered by physician and monitor for side effects and effectiveness; monitor resident for safety; monitor/document/report as needed any adverse reactions related to Anti-anxiety therapy and monitor/record occurrence of target behavior symptoms and document per facility protocol. However, the CCP was not developed with interventions to be implemented prior to adminsitration of a PRN antianxiety medication.
Review of Resident #53's CCP, revealed a focus of behavioral symptoms with an initiation date of [DATE]. The goal stated the resident would have behavioral symptoms managed with new or current interventions through target date. The interventions included: redirect resident when exhibiting inappropriate behaviors; approach resident with a positive attitude and smile; continue medications for anxiety as needed; Ativan (anti-anxiety medication) four (4) times a day routinely; Seroquel related to agitation/anxiety; continue medication related to depression; encourage resident to call for assistance with having shortness of air and observe every fifteen (15) minutes as needed; and offer sweets and coffee to redirect. However, the CCP was not developed to identify the resident's target behaviors.
Further review of the CCP, revealed a focus of antipsychotics with an initiation date of [DATE]. The goal stated the resident would be free from discomfort or adverse reactions to antipsychotic medications by next review. The interventions included: administer medications per order; monitor for side effects of medications including lethargy, weakness, falls, decline in activities of daily living, agitation, dizziness, and extrapyramidal signs or symptoms; and labs per orders.
Continued review of Resident #53's CCP, revealed a focus of antidepressant use with an initiation date of [DATE]. The goal stated the resident would be free from discomfort or adverse reactions related to antidepressant therapy through the review date. The interventions included: administer antidepressant medications as ordered; monitor as needed for adverse reactions to antidepressants, change in mood, behaviors, cognition, hallucinations, delusions, social isolation, suicidal thoughts, decline in Activities of Daily Living (ADLs), constipation, gait changes, balance problems, weight loss, fatigue, dizziness, tremors and dry mouth.
Review of Resident #53's Quarterly MDS Assessment, dated [DATE], revealed the facility assessed the resident as having a BIMS score of three (03) out of fifteen (15) indicating severe cognitive impairment. Further review revealed Section N-Medications, revealed Resident #53 received antipsychotic medication five (5) days; antianxiety medications five (5) days; and antidepressant medication five (5) days out of seven (7) days during the seven (7) day look back period.
Review of Resident #69's Monthly [DATE] Physician's Orders, revealed psychotropic medication orders for ABH Gel gel 0.5 milliliter (ml) to wrist every six (6) hours for behaviors with a start date of [DATE] (compounded drug containing Ativan, Benadryl and Haldol); Sertraline 25 mg at HS for depression with a start date of [DATE] (antidepressant medication); Lorazepam 1.0 mg at bedtime (HS) for anxiety with a start date of [DATE] (antianxiety medication); and Ziprasidone 20 mg twice a day for psychosis with a start date of [DATE] (antipsychotic medication).
Review of the Medication Administration Record (MAR) revealed a PRN (as needed) Lorazepam one (1) mg was administered on [DATE] at 9:30 PM, [DATE] at 10:00 PM, and [DATE] at 10:50 AM. However, review of the medical record revealed there was no documented evidence of behavioral health interventions implemented prior to pharmacological intervention nor was there documented justification for the PRN medication on [DATE], [DATE], and [DATE] . In addition, there was no documentation related to the effectiveness/ineffectiveness of the medication on these dates.
Review of the [DATE] Progress Notes, and [DATE] Progress Notes, revealed no documentation related to the resident's behaviors or lack of behaviors for the month.
Review of the Behavioral/Intervention Monthly Flow Record, dated [DATE], revealed there was a Flow Record for only one (1) of the three (3) prescribed psychotropic medications, Seroquel. The two (2) target behaviors listed for the medications was agitation and anxiety. There were one hundred eighty (180) opportunities for staff to document information including number of episodes, intervention, outcome and side effects for the day, evening and night shifts on the Flow Record; however, one hundred thirty-three (133) opportunities had incomplete documentation.
Review of the Behavioral/Intervention Monthly Flow Record, dated [DATE], revealed there was a Flow Record for only one (1) of the three (3) prescribed psychotropic medications, Seroquel. The one (1) target behavior listed for the medication was physical aggression. There were fifty (50) opportunities for staff to document information including number of episodes, intervention, outcome and side effects for the day, evening and night shifts on the Flow Record; however, thirty-six (36) opportunities had incomplete documentation.
There was no documented evidence of ongoing Psychotropic Drug use side effects and behavior symptom monitoring for Resident #53 related to any of the resident's Psychotropic medications per review of the Behavioral/Intervention Monthly Flow Records for June and [DATE], as outlined in the CCP.
Based on interview, record review, and review of facility policies, it was determined the facility failed to develop and implement a comprehensive person-centered care plan for each resident to meet the resident's mental and psychosocial needs for five (5) of twenty-one (21) sampled residents (Residents #3, #7, #18, #53, and #69).
There was no documented evidence Comprehensive Care Plans (CCPs) were consistently developed to identify target behaviors with individualized interventions to manage behavior symptoms for residents receiving Psychotropic Medications. In addition, there was no documented evidence the CCPs were consistently implemented related to monitoring behaviors and monitoring for adverse affects of psychotropic drugs. These failures affected Resident #3, #7, #18, #53, and #69. (Refer to F-758, and F-745)
The findings include:
Review of the facility's Care Planning-Interdisciplinary Team Policy, revised [DATE], revealed the facility would develop and implement a person centered care plan for each resident. Additionally, the Comprehensive Care Plan (CCP) was based on the resident assessment, (Minimum Data Set Assessment).
Review of the facility's Using the Care Plan Policy, revised [DATE], revealed the CCP was used in developing the resident's daily routine and documentation must be consistent with the resident's CCP.
Review of the facility's Behavior/Intervention Monthly Flow Record, revealed target behaviors, interventions, outcome and medication side effects would be monitored. Per the Flow Record, the number of behavior episodes was recorded in the box; a Potential Side Effect numerical Code or a blank box would indicate psychotropic drug use side effects; Outcome Interventions Codes were plus sign (+) for improved, zero (0) for unchanged and minus sign (-), for worsened.
1. Review of Resident #3's clinical record revealed the facility admitted the Resident on [DATE], with diagnoses including, but not limited to Alzheimer's Dementia, Major Depressive Disorder, Bipolar Disorder, and Anxiety Disorder.
Review of Resident #3's Comprehensive Care Plan (CCP), revised [DATE], revealed the resident received Buspar related to Anxiety Disorder. The goal stated the resident would be free from discomfort or adverse reactions related to antianxiety therapy. Interventions included: administer antianxiety medication as ordered by the physician and monitor for side effects and effectiveness; monitor the resident frequently for safety related to increase risk associated with taking antianxiety medication; and monitor/document/report as necessary adverse reactions of antianxiety medication such as lack of energy, confusion, aggressive impulsive behaviors, and hallucinations.
Continued review of Resident #3's CCP, revised [DATE] revealed the resident had Behavioral Symptoms including delusions, hallucinations, anger and aggressive behaviors related to diagnosis of Alzheimer's, Depression with Psychosis, Anxiety, Bipolar and Insomnia. The goal stated the resident would have fewer behavioral symptoms. Interventions included:monitor psychotropic medication changes as they occur. However, there was no documented evidence the CCP was developed to include individualized interventions for managing ongoing behavior symptoms.
Review of Resident #3's Quarterly Minimum Data Set (MDS) Assessment, dated [DATE] revealed the facility assessed the resident as having a Brief Interview for Mental Status (BIMS) score of seven (07) out of fifteen (15) indicating severe cognitive impairment. Per the MDS Assessment, the resident had no delirium, no hallucinations, and no delusions. Continued review revealed the facility assessed the resident as having no physical, verbal or other behavioral symptoms directed towards others; no rejection of care present and no wandering present. Further review revealed the resident received seven (7) days of antipsychotic, antianxiety, and antidepressant medication during the seven (7) day look back period.
Review of Resident #3's Monthly [DATE] Physician's Orders, revealed orders for psychotropic medication to include Bupropion 150 milligrams (mg) every twelve (12) hours twice a day for bipolar/depression, with a start date of [DATE] (antidepressant medication); Buspar 7.5 mg four (4) times a day for anxiety, with a start date of [DATE] (antianxiety medication); Risperidone 0.50 mg at HS (hour of sleep) for psychosis, with a start date of [DATE] (antipsychotic medication); Risperidone 0.25 mg once daily for psychosis, with a start date of [DATE]; Lamotrigine 200 mg every morning for Bipolar Disorder, with a start date of [DATE] (mood stablizer); and L-methylfolate 15 mg at HS for depression/mood, with a start date of [DATE] (form of folate used to treat depression).
Review of the Nurse's Note, dated [DATE] at 4:00 PM, revealed the resident was yelling out and talking about off the wall things; looking for his/her significant other who was deceased . Review of a subsequent Nurse's Note, dated [DATE] at 1:39 PM, revealed staff reported Resident #3 had not been in a very good mood over the past weekend, and the nurse spoke with the Psych Counselor concerning the resident's mood. Review of the Nurses Note, dated [DATE] at 11:15 AM, revealed new orders were received to send the resident to the hospital for further evaluation related to change in mental status and increased behaviors. According to the Note, the resident was upset, and continued to refuse to go.
Although Resident #3's Progress Notes, dated [DATE] at 4:00 PM; [DATE] at 1:39 PM; and [DATE] at 11:15 AM, revealed the resident was exhibiting mood/behaviors symptoms, there was no documented evidence of behavioral interventions or outcomes of the above behaviors or ongoing monitoring of behavioral symptoms as outlined in the CCP.
Review of the Behavior/Intervention Monthly Flow Record, dated 05/2019, revealed there was a Flow Record for only one (1) of five (5) prescribed psychotropic medications, Risperidone. There was one (1) target behavior listed for the medication, hallucinations. There were ninety (90) opportunities for staff to document information including number of episodes, intervention, outcome and side effects for the day, evening and night shifts on the Flow Record; however, twenty-eight (28) opportunities had incomplete documentation related to Risperidone medication.
Review of the Behavior/Intervention Monthly Flow Record, dated 06/2019, revealed there was a Flow Record for only one (1) of five (5) prescribed psychotropic medications, Risperidone. There was one (1) target behavior listed for the medication, hallucinations. There were ninety (90) opportunities for staff to document information including number of episodes, intervention, outcome and side effects for the day, evening and night shifts on the Flow Record; however, thirty-three (33) opportunities had incomplete documentation related to Risperidone medication.
Review of the Behavior/Intervention Monthly Flow Record, from [DATE] through [DATE], revealed there was a Flow Record for only one (1) of five (5) prescribed psychotropic medications, Risperidone. There was two (2) target behaviors listed which included verbal aggression and refusing care. There were ninety-six (96) opportunities for staff to document information including number of episodes, intervention, outcome and side effects for the day, evening and night shifts on the Flow Record; however, twenty-five (25) had incomplete documentation related to Risperidone medication.
Review of the Behavior/Intervention Monthly Flow Records for May, June, and [DATE], revealed failed opportunities to monitor behavior symptoms and psychotropic drug side effects. Further review revealed inaccurate documentation on the Flow Sheets as there was no documented evidence the behaviors documented in the Progress Notes on [DATE] at 4:00 PM; [DATE] at 1:39 PM; and [DATE] at 11:15 AM were captured on the Flow Sheets. Continued review revealed no documented evidence of ongoing Psychotropic Drug use side effects and behavior symptom monitoring per the Flow Sheets as outlined in the CCP.
2. Review of Resident #18's clinical record revealed the facility admitted the resident on [DATE], with diagnoses including, but not limited to Alzheimer's Disease, Paranoid Personality Disorder, Anxiety Disorder, Insomnia, and Recurrent Depressive Disorder.
Review of Resident #18's CCP, revised [DATE], revealed the resident received Seroquel Antipsychotic Medication related to Paranoid Personality Disorder. The goal stated the resident would be free from discomfort or adverse reactions to antipsychotic medications. Interventions included: administer medications per orders; monitor for side effects of medications such as lethargy, weakness, falls, decline in Activities of Daily Living, agitation; and monitor for target behaviors.
Continued review of Resident #18's CCP, revised [DATE], revealed the resident received Psychotropic Medications and was at risk for side effects. The goal stated the resident would not experience undesired effects from medication use. Interventions included: give medications as ordered; monitor for target behaviors; observe for side effects of medications; observe/document/notify for changes with medications adjustments. However, the CCP was not developed to identify the target behaviors.
Additional review of Resident #18's CCP, revised [DATE], revealed the resident received Antianxiety Medication related to anxiety. The goal stated the resident would be free from discomfort or adverse reactions. Interventions included: give medication per orders; monitor for safety; and monitor for side effects such as drowsiness, lack of energy, clumsiness, slow reflexes, slurred speech, confusion, disorientation and depression.
Continued review of Resident #18's CCP, revised [DATE], revealed the resident received Antidepressant Medications, Lexapro, Trazadone, and Remeron related to Depression, appetite, and insomnia. The goal stated the resident would be free from discomfort or adverse reactions related to antidepressant therapy. Interventions included: administer medication as ordered; monitor PRN (as needed)for adverse reactions to antidepressant medications such as change in mood, behaviors, cognition, hallucinations, delusions, social isolation, decline in Activities of Daily Living (ADLs, balance problems, weight loss, fatigue and dry mouth.
Review of Resident #18's Quarterly Minimum Data Set (MDS) Assessment, dated [DATE], revealed the facility assessed the resident as having a BIMS score of three (03) out of fifteen (15) indicating severe cognitive impairment. Per the MDS Assessment, the resident had no delirium, no hallucinations, and no delusions. However the facility assessed the resident as having disorganized thinking present and fluctuating. Continued review revealed the Resident had no physical, verbal or other behavioral symptoms directed towards others; no rejection of care present and no wandering present during the seven (7) day look back period. Further, the Resident received seven (7) days of antipsychotic, antianxiety, and antidepressant medication during the seven (7) day look back period.
Review pf Resident #18's CCP, revised [DATE], revealed the resident had behavior symptoms related to diagnosis of Alzheimer's/Dementia, anxiety, Paranoid Personality Disorder, Depressive Disorder, and insomnia; history of combativeness, agitation, delusions, cursing, and yelling. The goal stated the resident would have behavior symptoms managed with new and current interventions. Interventions included: report any behaviors to social services; continue medications for paranoia, insomnia, depression and anxiety; psych evaluation and treat for diagnosis; Haldol (antipsychotic) one (1) time dose [DATE]; and discontinue noon dose of Seroquel ([DATE]). However, the CCP was not developed with individualized interventions for managing ongoing behavior symptoms nor was the CCP developed with interventions for non-pharmalogical approaches prior to administration of PRN (as needed) psychotropic medications.
Review of the Monthly [DATE] Physician's Orders, revealed psychotropic medication orders for Citalopram 10 mg every morning for Depressive Disorder with a start date of [DATE] (antidepressant medication); Remeron 15 mg daily for Depressive Disorder with a start date of [DATE] (antidepressant medication); Trazadone 100 mg at bedtime for insomnia with a start date of [DATE] (antidepressant medication); Quetiapine Fumarate 25 mg three (3) times a day for Paranoid Personality Disorder with a start date of [DATE] (antipsychotic medication); Haldol 2 mg, one (1) time dose for increased anger, combativeness and aggression with a start date of [DATE] (antipsychotic medication); and Alprazolam 0.5 mg twice a day for anxiety with a start date of [DATE] (antianxiety medication).
Review of the Social Services' Note, dated [DATE] at 10:20 AM, revealed the resident switches from subject to subject, as conversation was illogical and the resident had a decline in health related to disease process.
Review of the Nurse's Note, dated [DATE] at 2:54 AM, revealed Resident #18 was talking to himself/herself as an aide went into the room; and the resident threatened, swung and cussed at the aide.
Review of the Nurse's Note, dated [DATE] at 3:20 AM, revealed Resident #18's representative was notified of behaviors and inquired as to why as needed (PRN) Haldol had been discontinued.
Continued review revealed the Nurse's Note, dated [DATE] at 4:57 AM, revealed Haldol 2 mg intramuscular one (1) dose now was administered related to increased anger, combativeness and aggression. However, the medical record revealed there was no documented evidence individualized ongoing behavioral health approaches were implemented prior to the pharmacological intervention.
Review of Resident #18's Nurse's Note, dated [DATE] at 12:24 AM, revealed the resident refused his/her medication after multiple attempts per the nurse.
Review of Resident #18's Nurse's Note, dated [DATE] at 1:26 PM, revealed the resident had a poor appetite all day and refused eating assistance from staff.
Review of Resident #18's Nurse's Note, dated [DATE] at 9:00 PM, revealed the resident was combative with an aide.
Although Resident #18's Progress Notes, [DATE] through [DATE] revealed seven (7) notes related to behavioral health symptoms dated [DATE] at 10:20 AM; [DATE] at 02:54 AM; [DATE] at 03:20 AM; [DATE] at 04:57 AM; [DATE] at 12:24 AM; [DATE] at 1:26 PM and on [DATE] at 9:00 PM. However, there was no documented evidence of behavioral interventions or outcomes related to the behaviors or ongoing monitoring of behavioral symptoms as outlined in the CCP.
Review of #18's Behavior/Intervention Monthly Flow Record, dated 05/2019, revealed there was a Flow Record for only one (1) of the five (5) prescribed psychotropic medications, Seroquel, with one (1) target behavior listed, Paranoia. There was ninety (90) opportunities for staff to document information including number of episodes, intervention, outcome and side effects for the day, evening and night shifts on the Flow Record; however, twenty-eight (28) opportunities had incomplete documentation per the Flow Record.
Review of Resident #18's Behavior/Intervention Monthly Flow Record, dated 06/2019, revealed there was a Flow Record for only one (1) of the six (6) prescribed psychotropic medications, Seroquel, with two (2) target behaviors listed including Paranoia, and combative behavior. There were one hundred eighty (180) opportunities for staff to complete documentation including number of episodes, intervention, outcome and side effects for the day, evening and night shifts on the Flow Record; however, fifty -seven (57) opportunities had incomplete documentation per the Flow Record.
Review of #18's Behavior/Intervention Monthly Flow Record, from [DATE] through [DATE], revealed there was a Flow Record for only one (1) one of the five (5) prescribed psychotropic medications, Seroquel, with two (2) target behaviors listed including combative and refuses care. There were ninety-six (96) opportunities for staff to document information including number of episodes, intervention, outcome and side effects for the day, evening and night shifts on the Flow Record; however, thirty (30) opportunities had incomplete documentation as per the Flow Record.
Further review revealed the Behavior/Intervention Monthly Flow Records dated 05/2019, 06/2019, and 07/2019, revealed failed opportunities to monitor behavioral symptoms and psychotropic drug side effects. In addition, there was inaccurate documentation as there was no documented evidence the behaviors noted in the Progress Notes dated [DATE] at 10:20 AM; [DATE] at 02:54 AM; [DATE] at 03:20 AM; [DATE] at 04:57 AM; [DATE] at 12:24 AM; [DATE] at 1:26 PM and on [DATE] at 9:00 PM were captured on the Flow Sheets. Continued review revealed no documented evidence of ongoing Psychotropic Drug use side effects and behavior symptom monitoring per the Flow Sheets as outlined in the CCP.
3. Review of Resident #69's clinical record revealed the facility admitted the resident on [DATE], with diagnoses including, but not limited to Alzheimer's Disease, Dementia with Lewy Bodies, Visual Hallucinations, Anorexia, Recurrent Depressive Disorder, and Anxiety Disorder.
Review of Resident #69's CCP, revised [DATE], revealed the resident received Ativan related to Anxiety Disorder, Psychosis, Lewy Body, and [NAME] Bonnet Syndrome and had target behaviors including visual and audio hallucinations, accusations, aggression towards staff, verbally abusive, and refuses care. The goal stated the resident would be free from discomfort or adverse reactions related to antianxiety therapy. Interventions included administer antianxiety medications as ordered and monitor for side effects and effectiveness; monitor/document/report as needed adverse reactions to antianxiety therapy and monitor/record occurrences of target behavior symptoms and document per facility protocol.
Continued review of Resident #69's CCP, revised [DATE] revealed the resident received Antidepressant medication, Zoloft related to Depression. The goal stated the resident would be free from discomfort or adverse reaction related to antidepressant therapy. Interventions included administer antidepressant medications as ordered; and monitor for adverse reactions to antidepressants, such as change in mood, behaviors, hallucinations, delusions, weight loss, and fatigue.
Additional review of Resident #69's CCP, revised [DATE], revealed the resident received antipsychotic medications including ABH gel and Geodon related to Dementia and Psychosis. The goal stated the resident would be free from discomfort of adverse reactions to antipsychotic medications. Interventions included monitor for side effects of medications such as lethargy, weakness, falls, decline in Activities of Daily Living (ADLs), agitation, and dizziness.
Continued review of Resident #69's CCP, revised [DATE], revealed the resident received Psychotropic Drugs and had multiple behaviors daily. The goal stated the resident would be/remain free of psychotropic drug related complications or behavioral impairment. Interventions included administer psychotropic medication as ordered and monitor for side effects and effectiveness; monitor for target behaviors; and monitor/record occurrences of target behaviors and document per the facility protocol.
Further review of Resident #69's CCP, revised [DATE], revealed the resident had behavioral symptoms such as hallucinations, delusions, paranoia, and combativeness. The goal stated the resident would remain safe despite behavioral symptoms. Interventions included monitor for hallucinations and delusions for improvement or worsening and continue medications related to psychiatric diagnoses.
Review of the Progress Notes, dated [DATE] at 10:30 PM, revealed the resident was having tearful episodes related to being lonely and having nobody to talk to and feeling like family was not caring about him/her anymore. Per the Notes, tender loving care given to the resident and he/she appeared calmer. Further review revealed a Nurse's Note, dated [DATE] at 9:00 PM, revealing the resident was noted sitting naked on the floor with television on his/her right foot.
However, review of the Progress Notes, dated [DATE] at 10:30 PM and [DATE] at 9:00 PM, revealed there was no documented evidence of behavioral interventions or outcomes of the above behaviors or ongoing monitoring of behavioral symptoms as outlined in the CCP.
Review of Resident #69's Quarterly Minimum Data Set (MDS) Assessment, dated [DATE], revealed the facility assessed the resident as having a BIMS score Mental of eleven (11) out of fifteen (15) indicating moderate cognitive impairment. Per the MDS Assessment, the resident had no delirium, no hallucinations, no delusions, and no behaviors during the look back period. Further, the facility assessed the resident as receiving seven (7) days of antipsychotic, antianxiety, and antidepressant medications out of the past seven (7) days. However, the documented behavioral events in the medical record during the look back period were not captured in the MDS Assessment (Refer to F-641).
Review of the Monthly [DATE], Physician's Orders, dated [DATE] revealed psychotropic medication orders for ABH Gel gel 0.5 milliliter (ml) to wrist every six (6) hours for behaviors with a start date of [DATE] (compounded drug containing Ativan, Benadryl and Haldol); Sertraline 25 mg at HS for depression with a start date of [DATE] (antidepressant medication); Lorazepam 1.0 mg at bedtime (HS) for anxiety with a start date of [DATE] (antianxiety medication); and Ziprasidone 20 mg twice a day for psychosis with a start date of [DATE] (antipsychotic medication).
Review of the Behavior/Intervention Monthly Flow Record, dated 05/2019 revealed only one (1) of four (4) prescribed psychotropic medications, Geodon (ziprasidone), had a Flow Record with two (2) target behaviors listed including hallucinations and delusions. There were ninety-three (93) opportunities for staff to complete documentation including number of episodes, intervention, outcome and side effects for the day, evening and night shifts on the Flow Record; however, twenty-three (23) opportunities had incomplete documentation.
There was no documented evidence of a Behavior/Intervention Monthly Flow Record for [DATE].
Review of the Behavior/Intervention Monthly Flow Record, dated 07/2019 revealed only one (1) of the four (4) prescribed psychotropic medications, Geodon, had a Flow Record with two (2) target behaviors listed including hallucinations and delusions. There were fifty-one (51) opportunities for staff to complete documentation including number of episodes, intervention, outcome and side effects for the day, evening and night shifts on the Flow Record; however, seventeen (17) opportunities had incomplete documentation.
Further review revealed the Behavior/Intervention Monthly Flow Records dated 05/2019, and 07/2019, revealed inaccurate documentation as behaviors were not captured as compared to behaviors noted otherwise in the medical record. In addition, there was no documented evidence of individualized behavioral interventions and no documented evidence of consistent Psychotropic Drug use side effects and behavior symptom monitoring as outlined in the CCP.
5. Review of Resident #7's clinical record revealed the facility admitted the resident on [DATE], with diagnoses including, but not limited to Dementia with Behavioral Disturbances, Anxiety Disorder, and Depressive Disorder.
Review of Resident #7's Quarterly Minimum Data Set (MDS) Assessment, dated [DATE], revealed the facility assessed the resident as having a BIMS score of three (03) out of fifteen (15) indicating severe cognitive impairment. Per the MDS Assessment, the resident was assessed as having no delirium, no hallucinations, and no delusions. Continued review of the MDS Assessment revealed the facility assessed the resident as having no physical, verbal or other behavioral symptoms directed towards others; as exhibiting no rejection of care or wandering during the look back period. Further, the resident was assessed as receiving antipsychotic, antianxiety, and antidepressant medication seven (7) days out of the past seven (7) days.
Review of Resident #7's Comprehensive Care Plan, revised [DATE], revealed the resident received Seroquel (antipsychotic medication), Buspar (antianxiety medication) and Pristiq medication to treat depression) related to Major Neurocognitive Disorder, Anxiety Disorder and Major Depression. The goal stated the resident would not experience any undesired effects from medication use through next review. Interventions included: attempt gradual dose reductions per federal regulation unless clinically contraindicated indications are known, monitor target behaviors, and Psych to see as ordered. However, the CCP was not developed to identify the target behaviors.
Additional review of Resident #7's Comprehensive Care Plan, revised [DATE] revealed the resident receiv[TRUNCATED]